Эпигенетика

Grady W.M., Wilis J., Guilford P.J., Dunbier A.K., Toro T.T., Lynch H., Wesner G., Ferguson K., Eng C, Park J.G., et al., 2000. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. Genet. 26: 16-17.

Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C., 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.

Gregorieff A. and Clevers H., 2005. Wnt signaling in the intestinal epithelium: From endoderm to cancer. Genes Dev., 19: 877-890.

Hanahan D. and Weinberg R.A., 2000. The hallmarks of cancer. Cell 100: 57-70.

Herman J.G. and Baylin S.B., 2003. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349: 2042-2054.

Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., Markowitz S., Wilson J.K., Hamilton S.R., Kinzler K.W, et al., 1998. Incidence and functional consequences of hMLHl promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci 95: 6870-6875.

Holm T.M., Jackson-Grusby L., BrambrinkT., Yamada Y, Rideout W.M., III, and Jaenisch R., 2005. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8: 275-285.

Holst C.R., Nuovo G.J., Esteller M., Chew K., Baylin S.B., Herman J.G., and Tlsty T. D., 2003. Methylation ofplG^lNK4a promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63: 1596-1601.

Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., et al., 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.

Issa J.P., Ottaviano Y.L., Celano P., Hamilton S.R., Davidson N.E., and Baylin S.B., 1994. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon Nat. Genet. 7: 536-540.

Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., Bayar E., Lyons J., Rosenfeld C.S., Cortes J., and Kantaijian H.M. 2004. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640.

Jones P.A., 1999. The DNA methylation paradox. Trends Genet. 15: 34-37.

Jones PA. and Baylin S.B., 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415-428.

Jones P.A. and Laird P.W, 1999. Cancer epigenetics comes of age. Nat. Genet. 21: 163-167.

Jones P.A. and Taylor S.M., 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell, 20: 85-93.

Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.-L., Leighton J.K., Patel H., Rahman A., Sridhara R., et al., 2005. Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11: 3604-3608.

Kaneda A. and Feinberg A.P., 2005. Loss of imprinting of IGF2: A common epigenetic modifier of intestinal tumor risk. Cancer Res. 65: 11236-11240.

Katzenellenbogen R.A., Baylin S.B., and Herman J.G., 1999. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93: 4347-4353.

Kinzler K.W. and Vogelstein B., 1997. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761-763.

Kiyono T, Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., and Klingelhutz A.J., 1998. Both Rb/pl6^INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88.

Knudson A.G., 2001. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1: 157-162.

Kondo Y., Shen L., and Issa J.R, 2003. Critical role ofhistone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell. Biol. 23: 206-215.

Kuzmichev A., Margueron R., Vaquero A., PreissnerT.S., Scher M., KirmizisA., OuyangX., BrockdorffN., Abate-ShenC., Famham P., and Reinberg D., 2005. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. 102: 1859-1864.

Laird P.W., 2003. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3: 253-266.

Laird P.W., Jackson-Grusby L., Fazeli A., Dickinson S.L., Jung W.E., Li E., Weinberg R.A., and Jaenisch R., 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81: 197-205.

Lapeyre J.N. and Becker F.F., 1979. 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem. Biophys. Res. Commun. 87: 698-705.